{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+%28EYLEA%C2%AE%29", "query": { "intervention": "Aflibercept (EYLEA®)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 67, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+%28EYLEA%C2%AE%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T22:19:28.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03610646", "title": "Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "MYL-1701P", "type": "DRUG" }, { "name": "Eylea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2018-08-23", "completion_date": "2021-09-10", "has_results": true, "last_update_posted_date": "2023-03-07", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610646" }, { "nct_id": "NCT02401945", "title": "A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "DE-120", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 16, "start_date": "2015-04", "completion_date": "2016-10-31", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Golden", "state": "Colorado" }, { "city": "Altamonte Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401945" }, { "nct_id": "NCT04429503", "title": "Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetic Macular Edema", "Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "aflibercept", "type": "DRUG" }, { "name": "High-dose aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2020-06-29", "completion_date": "2024-06-18", "has_results": true, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 84, "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04429503" }, { "nct_id": "NCT07496567", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-04-15", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Encino, California • Mountain View, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07496567" }, { "nct_id": "NCT03374670", "title": "ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Polypoidal Choroidal Vasculopathy" ], "interventions": [ { "name": "Zimura", "type": "DRUG" }, { "name": "Eylea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2018-11", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 1, "location_summary": "‘Aiea, Hawaii", "locations": [ { "city": "‘Aiea", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374670" }, { "nct_id": "NCT05989126", "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema (DME)", "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "aflibercept 8 mg PFS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2024-04-15", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 2, "location_summary": "Bellaire, Texas • The Woodlands, Texas", "locations": [ { "city": "Bellaire", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989126" }, { "nct_id": "NCT00561470", "title": "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1226, "start_date": "2007-11", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-09-28", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561470" }, { "nct_id": "NCT06321302", "title": "A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "BI 764524", "type": "DRUG" }, { "name": "Sham comparator to BI 764524", "type": "DRUG" }, { "name": "Aflibercept (Eylea®) - US only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2024-05-15", "completion_date": "2027-08-20", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06321302" }, { "nct_id": "NCT02713204", "title": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "REGN910-3", "type": "DRUG" }, { "name": "Intravitreal Aflibercept Injection (IAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 365, "start_date": "2016-03-31", "completion_date": "2017-10-03", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 87, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713204" }, { "nct_id": "NCT02214628", "title": "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Fovista® (anti-PDGF BB) plus anti-VEGF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 101, "start_date": "2014-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-09-30T22:19:28.008Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214628" } ] }